南京医科大学学报（自然科学版）2024，Vol.44Issue(5)：688-697,10.DOI:10.7655/NYDXBNSN240078
胶质母细胞瘤对替莫唑胺耐药机制的研究进展
Research progress on the mechanism of temozolomide resistance in glioblastoma
摘要
Abstract
The small molecule alkylating agent temozolomide(TMZ)is commonly used as a frontline therapy for glioblastoma(GBM).However,there are certain factors,such as the presence of O-6-methylguanine-DNA methyltransferase(MGMT)and activated DNA repair pathways,that can lead to resistance to TMZ,thereby limiting its effectiveness.This paper aims to comprehensively review the detailed molecular mechanisms of TMZ resistance,discuss innovative therapeutic strategies to overcome resistance,and explore potential drugs that may enhance the efficacy of TMZ.Ultimately,our goal is to provide valuable insights into clinical approaches for mitigating TMZ resistance in GBM patients.关键词
胶质母细胞瘤/替莫唑胺/耐药机制/治疗策略Key words
glioblastoma/temozolomide/resistance mechanisms/treatment strategies分类
医药卫生引用本文复制引用
李盈盈,冯黎黎,韩峰..胶质母细胞瘤对替莫唑胺耐药机制的研究进展[J].南京医科大学学报（自然科学版）,2024,44(5):688-697,10.基金项目
国家重点研发计划(2022YFE0104800) （2022YFE0104800）
